Shares of Evoq Remedies Ltd were locked at 20% upper circuit on 10 January after the company received an export order worth Rs 136 crore.

In its regulatory filing, the company said that they have secured an export order worth Rs 136 Crore from Marlexx Pharma Inc., a US-based company for delivering high-quality pharmaceutical products.

The company has received orders to supply pharmaceutical products, including Tramadol Hydrochloride API, Lisinopril API Powder, Metformin API, Piperacillin Sodium Sterile, and many more.

The order received is six times greater than compared to the company’s market capitalization.

As of 31 September, the promoters of the company hold a 73.53% stake in the company, whereas the remaining 26.47% stake is held by retail investors.

The company has its headquarters located in Ahmedabad and is engaged in the trading of pharmaceutical formulations and allied products.

At 3:30 pm, the shares of Evoq Remedies closed 20% higher at Rs 16.20 on BSE.